Translational Vaccinology for Human Health

October 25–29, 2016 | Park Plaza Riverbank | London | United Kingdom

Scientific Organizers:

Christopher L. Karp, Bill & Melinda Gates Foundation, USA
Gagandeep Kang, Christian Medical College, India
Rino Rappuoli, GlaxoSmithKline Vaccines, Italy

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

The time required to launch new global health vaccines is too long and the late failure rate is unsustainably high. Key barriers include insufficient diversity and quality of preclinical concepts and candidates, immunobiological ignorance, and a lack of understanding of correlates or mechanisms of protection. Root causes include siloed science and linear thinking; poor integration across the discovery/development/delivery ecosystem; and slow entry and limited throughput in early human proof-of-concept testing. This Keystone Symposia meeting aims to bring together those pioneering novel, creative solutions to these problems of global vaccine discovery and development across the academic/biotech/product development partner/pharma spectrum.

Session Topics:
• Controlled Human Infection Models
• Workshop 1: Correlates of Protection
• Human Immune Profiling
• Toward PK/PD in B Cell Vaccinology
• Workshop 2: Human Immunophenotyping
• T Cells
• Novel Approaches to Antigen Identification and Immunogen Design
• Adjuvants, Mucosal and Otherwise
• Clinical Trial Readouts
• Workshop 3: Antigen Identification, Adjuvants, Formulations and Novel Delivery Platforms
• Accelerating Global Health Vaccine R&D

Abstract Deadline: July 26, 2016
Discounted Registration Deadline: August 25, 2016

Note: Short talks on the program will be selected from abstracts submitted by the abstract deadline.

Meeting Hashtag: #KSvax
www.keystonesymposia.org/16S1

KEYSTONE SYMPOSIA
on Molecular and Cellular Biology
Accelerating Life Science Discovery
www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230
a 501(c)(3) nonprofit educational organization